Investor Presentaiton

Company overview Financial performance Oncology Immunology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars BeovuⓇ - VEGF Inhibitor NCT04278417 (CRTH258D2301) Diabetic retinopathy Indication Phase Phase 3 Patients 706 Primary Change from Baseline in BCVA Outcome Measures Arms Intervention Arm1: RTH258 (brolucizumab) 6 mg/50uL Arm2: Panretinal photocoagulation laser initial treatment followed with additional PRP treatment as needed Target Patients Patients with proliferative diabetic retinopathy Read-out Milestone(s) 2024 Publication TBD 78 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation